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INTRODUCTION:  The  prognosis  of  patients  with  lung  cancer  metastasis  to  the  spine  is not  very  promising
and  a palliative  approach  is  often  suggested  by scales  such  as the  Tomita  score.  The  choice  of  surgery
for  these  patients  is  questionable  based  on  the aggressiveness  of the  disease.  However,  certain  patient
characteristics  can  be sought  out  to determine  if  surgery  is  indicated.
PRESENTATION OF  CASE:  Here,  we  present  a case  of  a 59  year old  male  which  consulted  for  back  pain,
numbness  of the  upper  left  thigh,  and weakness  corresponding  to an L2  lesion.  It was  later  discovered
that  he was  suffering  from  non  small  cell  lung  cancer  (adenocarcinoma)  with  a single  metastasis  to  the
spine  at the level  of  L2.  The  patient  also  presented  an  EGFR  mutation.  Thus,  the  patient  presented  two
good  prognosis  characteristics:  adenocarcinoma  and  an  EGFR  mutation.
DISCUSSION: An  aggressive  treatment  was  chosen.  This  included  an  EGFR  inhibitor,  surgical  treatment,denocarcinoma and  radiotherapy  thereafter.  The  patient  had  no  complications  due  to  surgery  and  to  date,  the  patient  has
survived  over  12  months  and  is  free  of any  symptoms.  This  case  demonstrates  that  surgical  intervention
can  be considered  for certain  patients  with  lung  cancer  metastasized  to the  spine.
CONCLUSION: This  case  demonstrates  that surgical  intervention  can  be  considered  for  certain  patients
with  lung  cancer  metastasized  to the  spine.  We  hope  spine  surgeons  in  general  will  start  verifying  the
EGFR  mutation  status  of  adenocarcinoma  lung  cancer  patients  to  determine  if surgery  is  indicated.
gical A© 2012 Sur
. Introduction
The prognosis of patients with lung cancer metastasis to the
pine is not very promising and a palliative approach is often sug-
ested by scales such as the Tomita score. The choice of surgery for
hese patients is questionable based on the aggressiveness of the
isease. Sugiura et al.1 reported that the survival rates of patients
fﬂicted with lung cancer metastasized to the spine was  59.9% at
 months, 31.6% at 1 year, and only 11.3% at 2 years. Although
hese survival rates are low, the identiﬁcation of patients with
etter prognosis becomes essential for their clinical management.
hus, the identiﬁcation of patient characteristics that can help iden-
ify those with higher survivorship is required. Fortunately, new
dvancements in the ﬁeld have identiﬁed markers that can help
dentify those with better prognosis and allow for new treatment
ptions which have also been shown to improve survivorship. We
uggest that cancer type and presence of Epithelial Growth Fac-
or Receptor (EGFR) mutation can be used to identify those with
etter survivorship and those who can beneﬁt from more aggres-
ive treatment such as surgery. We  suggest that these prognosis
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indicators be considered while assessing the potential surgical
treatment of patients.
2.  Presentation of case
Here we present a case of a 59 year old male which consulted
for back pain (Visual Analog Scale of 5/10), numbness of the upper
left thigh, and weakness corresponding to an L2 lesion. The patient
had no other signs or symptoms, no signiﬁcant past medical history,
but did have a history of smoking (9 pack-years) 35 years ago. Upon
arrival to the emergency room a CT scan and X-ray of the spine were
taken. An abnormal mass was  noted at the level of L2 and the left
upper lobe of the lung. Further investigation with MRI, PET scan,
and biopsies of the vertebral and pulmonary lesions conﬁrmed the
diagnosis of single metastasis lesion at the level of L2. The primary
site was the lung with staging of T1N0M1. The lesion was conﬁrmed
to be NSCLC (adenocarcinoma). A mutation to the EGFR gene was
identiﬁed (deletion of Exon 19). The MRI  showed pedicle involve-
ment and spinal canal stenosis. The vertebral lesion spanned the
entire L2 vertebrae and was  estimated to measure 4.2 cm in width,
Open access under CC BY-NC-ND license.3.3 cm in length, and 3 cm in height (refer to Fig. 1).
Despite the aggressiveness of the disease, this patient presented
two good prognosis characteristics: adenocarcinoma and an EGFR
mutation. Therefore, an aggressive treatment was  chosen. This
 BY-NC-ND license.
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RFig. 1. Pre-operative MRI  showing a lesion at the level of L2 (lung cance
ncluded an EGFR inhibitor, surgical treatment, and radiotherapy
hereafter.
The surgical treatment consisted of an anterior vertebrectomy of
2 via retroperitoneal approach followed by installation of a cage
laced between L1 anmd L3 and posterior transcutaneous pedi-
le screw placement from T12 to L4 (refer to Fig. 2). The patient’s
otal length of stay for the surgery was 6 days. He fully recov-
red and had no complications due to surgery. His post-operative
AS was reduced to 1. The patient’s numbness and weakness was
ully recovered immediately following surgery. He was  followed
t 2 weeks, 1 month, 4 month, and 7 months without recurrence
f numbness or weakness or any other complication. He was  also
reated with radiotherapy (45 Gy) localized to the spine and lung
fter surgery. The patient supported radiotherapy without any
ssociated complications.
.  Discussion
Here we presented case of lung cancer adenocarcinoma metas-
asized to the spine with EGFR mutation. We  treated this patient
ggressively based on the good prognosis characteristics he pre-
ented. To date, the patient has survived over 12 months and is
ree of any symptoms. He can walk on his own  and does not
ave any respiratory complications. This case demonstrates that
urgical intervention can be considered for certain patients with
ung cancer metastasized to the spine. Although survivorship of
hese patients can be very low,1 certain patient characteristics
hould be sought out to determine if surgery can be a good treat-
ent option. We  suggest that surgical intervention should be
onsidered for patients with lung cancer metastasized to the spine
ig. 2. Post-operative X-ray showing vertebrectomy of L2, cage placed between L1 and L3
ight:  coronal view.ocarcinoma metastasis). Left: transverse view of L2. Right: sagital view.
who  have EGFR mutation and adenocarcinoma. It is evident that
other factors should be considered before surgical intervention,
such as number and location of metastases and overall patient
health. However our results demonstrate that these characteristics
should be veriﬁed and used to determine if surgical intervention is
justiﬁed.
Our observations and results concur with the literature. For
instance, it has been shown that better survivorship was found for
patients with adenocarcinoma and those treated with Epithelial
Growth Factor Receptor (EGFR) inhibitors.1 In fact, several reports
have shown the effectiveness of EGFR inhibitors for the treatment
of lung cancer (especially adenocarcinoma).2–5 In addition, patients
with lung cancer and mutation to the EGFR gene can further ben-
eﬁt from EGFR inhibitors.6 Other studies have also demonstrated
reduced lung cancer cell proliferation and tumor regression with a
combination of an EGFR inhibitor and antiestrogens7,8; suggesting
that estrogen receptors (ER) and EGFR have a role in the carcinogen-
esis of non-small cell lung cancer (NSCLC).7–10 Yet another study
has demonstrated that the presence of ER can be used as a prog-
nosis indicator for patients with surgically resected NSCLC such
as adenocarcinoma.11 These encouraging oncology ﬁndings should
become familiar to most spine surgeons.
We suggest that these prognosis indicators be considered while
assessing the potential surgical treatment of our patients. More
speciﬁcally, EGFR mutations should be veriﬁed for patients with
lung cancer adenocarcinoma metastasized to the spine. As demon-
strated in this case, these can be indication for surgery and improve
quality of life. Our study is limited to one case and a study looking
at correlation of survivorship and EGFR mutation should be con-
sidered to determine the true relationship between presence of
 and posterior pedicle screws placed at T12, L1, L3, and L4. Left: sagital view of L2.
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GFR mutation and survivorship. However, the positive outcomes
f this case should motivate surgeons to verify oncological markers
o optimize treatment choice for their patients.
. Conclusion
Here we show a case with good results and good recovery based
n surgical treatment, an option that is normally overlooked for
atients with lung cancer metastasized to the spine. We  suggest
hat EGFR mutation be veriﬁed for patients with lung cancer metas-
asized to the spine. We  also encourage spine surgeons to consider
urgical treatment of patients with both EFGR mutation and iden-
iﬁed adenocarcinoma based on the good results we observed.
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